Clinical Trials Directory

Trials / Completed

CompletedNCT05498324

External Validation of the 4C Mortality Score for Hospitalised Patients With COVID-19 in a Tunisian Cohort

Status
Completed
Phase
Study type
Observational
Enrollment
1,500 (actual)
Sponsor
University of Monastir · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

Risk prediction scores are important tools to support clinical decision-making for patients with coronavirus disease (COVID-19). The objective of this paper was to validate the 4C mortality score, originally developed in the United Kingdom, for a tunisian population, and to examine its performance over time.

Detailed description

Coronavirus disease (COVID-19) caused by the Severe Acute Respiratory Syndrome Virus 2 (SARS-CoV-2) can progress to acute respiratory distress syndrome, multiorgan failure, and death in some cases. The clinical presentation and progression of COVID-19 in patients is highly variable, which makes it difficult for clinicians to triage patients and determine their prognostic risk. A simple, validated prognostic tool using data that is available at presentation can help clinicians better prognosticate and support clinical decision-making . Numerous tools to predict mortality in COVID-19 patients have been developed, but many are limited due to small derivation cohort sizes and/or inadequate validation. The 4C mortality score is an accessible risk stratification score developed by the International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC). It was derived and internally validated on a large, diverse cohort within the United Kingdom but requires external validity to confirm its generalizability. The objective of this study was to validate the 4 C Mortality risk score to predict in-hospital mortality among adults hospitalised with COVID-19 in a Tunisian cohort. .

Conditions

Timeline

Start date
2020-11-01
Primary completion
2022-04-30
Completion
2022-04-30
First posted
2022-08-12
Last updated
2023-05-16

Locations

1 site across 1 country: Tunisia

Source: ClinicalTrials.gov record NCT05498324. Inclusion in this directory is not an endorsement.